We have previously reported the generation of the IOE11 TERT-immortalized ovarian surface epithelial cell line23 (
link). IOE11 cultured in NOSE-CM52 (
link). To generate a p53-deficient line, IOE11 cells were transfected with
T7-p53DD-pcDNA3 (Addgene plasmid number 25989) and positive clones (IOE11-DNp53) selected with 125 μg ml
−1 G418. Loss of p53 function was confirmed by irradiating IOE11-DNp53 and control cells with 6 Gy ionizing radiation and immunoblotting cell lysates for p21 expression (
sc-397, 1:1,000 dilution, Santa Cruz Biotechnology) 24 h later. Immortalized fallopian tube secretory epithelial cell lines (FT33-shp53-R24C and FT246-shp53-R24C) have been previously described22 (
link) and were cultured in
DMEM/F12 (Sigma) supplemented with 2% Ultroser G (Crescent Chemicals) or 10% fetal bovine serum (FBS; Hyclone, Thermo Fisher). For 3C, HEY cells were grown in RPMI containing 10% FBS and OVCA429 cells were cultured in EMEM supplemented with 10% FBS, 1 × non-essential amino acids and 1 × sodium pyruvate. All cell lines used in this study were routinely tested for
Mycoplasma infection using a
Mycoplasma-specific PCR, and, for cell line authentication, short tandem repeats profiled using the
PowerPlex16HS Assay (Promega, University of Arizona Genetics Core).
Lawrenson K., Li Q., Kar S., Seo J.H., Tyrer J., Spindler T.J., Lee J., Chen Y., Karst A., Drapkin R., Aben K.K., Anton-Culver H., Antonenkova N., Baker H., Bandera E.V., Bean Y., Beckmann M.W., Berchuck A., Bisogna M., Bjorge L., Bogdanova N., Brinton L.A., Brooks-Wilson A., Bruinsma F., Butzow R., Campbell I.G., Carty K., Chang-Claude J., Chenevix-Trench G., Chen A., Chen Z., Cook L.S., Cramer D.W., Cunningham J.M., Cybulski C., Dansonka-Mieszkowska A., Dennis J., Dicks E., Doherty J.A., Dörk T., du Bois A., Dürst M., Eccles D., Easton D.T., Edwards R.P., Eilber U., Ekici A.B., Fasching P.A., Fridley B.L., Gao Y.T., Gentry-Maharaj A., Giles G.G., Glasspool R., Goode E.L., Goodman M.T., Grownwald J., Harrington P., Harter P., Hasmad H.N., Hein A., Heitz F., Hildebrandt M.A., Hillemanns P., Hogdall E., Hogdall C., Hosono S., Iversen E.S., Jakubowska A., James P., Jensen A., Ji B.T., Karlan B.Y., Kruger Kjaer S., Kelemen L.E., Kellar M., Kelley J.L., Kiemeney L.A., Krakstad C., Kupryjanczyk J., Lambrechts D., Lambrechts S., Le N.D., Lee A.W., Lele S., Leminen A., Lester J., Levine D.A., Liang D., Lissowska J., Lu K., Lubinski J., Lundvall L., Massuger L.F., Matsuo K., McGuire V., McLaughlin J.R., Nevanlinna H., McNeish I., Menon U., Modugno F., Moysich K.B., Narod S.A., Nedergaard L., Ness R.B., Azmi M.A., Odunsi K., Olson S.H., Orlow I., Orsulic S., Weber R.P., Pearce C.L., Pejovic T., Pelttari L.M., Permuth-Wey J., Phelan C.M., Pike M.C., Poole E.M., Ramus S.J., Risch H.A., Rosen B., Rossing M.A., Rothstein J.H., Rudolph A., Runnebaum I.B., Rzepecka I.K., Salvesen H.B., Schildkraut J.M., Schwaab I., Sellers T.A., Shu X.O., Shvetsov Y.B., Siddiqui N., Sieh W., Song H., Southey M.C., Sucheston L., Tangen I.L., Teo S.H., Terry K.L., Thompson P.J., Timorek A., Tsai Y.Y., Tworoger S.S., van Altena A.M., Van Nieuwenhuysen E., Vergote I., Vierkant R.A., Wang-Gohrke S., Walsh C., Wentzensen N., Whittemore A.S., Wicklund K.G., Wilkens L.R., Woo Y.L., Wu X., Wu A.H., Yang H., Zheng W., Ziogas A., Monteiro A., Pharoah P.D., Gayther S.A, & Freedman M.L. (2015). Cis-eQTL analysis and functional validation of candidate susceptibility genes for high-grade serous ovarian cancer. Nature Communications, 6, 8234.